Company intelligence / Profile preview

Armaron Biosciences

Marina Del Rey, California, United Statesarmra.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Armata has completed three critical Phase 2 trials, two of which were completed in 2024, utilizing two distinct phage cocktails against different pathogens. Their lead candidates AP-PA02 and AP-SA02 are being evaluated for respiratory infections and staphylococcal infections respectively. The company is moving toward pivotal Phase 3 clinical studies.[4][8]

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Phage therapyBacteriophage cocktails
Industry: Biotech

Drug pipeline

4 assets

XEN1101

Phase 2

Indications: Focal epilepsy

3 more assets in the full pipeline.

Request access →

Partnerships

US Department of Defense (DoD)

Beyond the preview

Go deeper on Armaron Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Armaron Biosciences.

Explore the full profile